Teva wins FDA approval for monthly schizophrenia injection Weltruza
TEVA•Teva said the FDA approved Weltruza as the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia. The company expects to launch it in the United States in the coming weeks.
1. FDA approval
Teva said on Friday it received FDA approval for Weltruza, an extended-release injectable suspension for adults with schizophrenia. The company described it as the first and only once-monthly subcutaneous injectable olanzapine.
2. U.S. launch expected
Teva, which is leading the treatment’s development and commercialization under a partnership with France’s Medincell, expects to launch Weltruza in the United States in the coming weeks.
